EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL

Candice Jamois iD, David C Turner iD, Leonid Gibiansky iD, Feifei Li iD, Jean-Francois Menuet, Leonardo Roque Pereira iD, Linda Lundberg iD, Elena Guerini, David J Carlile iD, James Relf, Michael C Wei, Antonia Kwan und 2 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Candice Jamois und 13 weiteren Autor:innen. Beteiligte Einrichtung: Roche Innovation Center Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Cytokine Release Syndrome, T-Lymphocytes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent surge in T‐cell‐engaging and chimeric antigen receptor (CAR) T‐cell therapies is changing the landscape of cancer therapy. Cytokine release syndrome (CRS) is a systemic inflammatory response syndrome that is a well‐known complication of these therapies, of which interleukin‐6 (IL‐6) is a key mediator. Tocilizumab, an IL‐6 receptor (IL‐6R) antagonist, is approved for the management of CAR T‐cell therapy‐induced CRS in adults and in pediatric patients aged ≥ 2 years old. However, the approved dosing schedule was not based on IL‐6R occupancy and may not be the most suitable schedule for T‐cell‐engaging therapies such as bispecific antibodies (bsAb) due to key differences in the levels of released IL‐6, the clinical symptomatology of CRS, and the pharmacology of tocilizumab across settings. In this study, we adapted a previously developed tocilizumab and soluble IL‐6R (sIL‐6R) population pharmacokinetic model to describe and predict tocilizumab concentrations and sIL‐6R occupancy over time in patients with anti‐CD20 bsAb‐induced CRS following tocilizumab dosing. Using this model, which incorporates target binding and receptor occupancy, we propose a new tocilizumab dosing regimen that is based on quantitative clinical pharmacology, cytokine analyses, and clinical practice patterns in patients with relapsed/refractory B‐cell non‐Hodgkin's lymphoma (R/R B‐NHL) treated with the anti‐CD20 bsAb mosunetuzumab or glofitamab. This schedule (up to two 8 mg/kg intravenous tocilizumab doses per CRS event at least 8 hours apart and a maximum of three doses in 6 weeks) can be used to effectively manage acute CRS induced by anti‐CD20 bsAb in patients with R/R B‐NHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntibodies, BispecificCytokine Release SyndromeT-LymphocytesLymphoma, B-CellAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedReceptors, Interleukin-6AdultAgedInterleukin-6Dose-Response Relationship, Drug

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedAntibodies, BispecificReceptors, Interleukin-6Interleukin-6Antineoplastic Agents, ImmunologicalIL6R protein, human

Autor:innen und Institutionen

  • Roche Innovation Center Basel, Basel, Switzerland.
  • Genentech, Inc., South San Francisco, California, USA.
  • QuantPharm LLC, North Potomac, Maryland, USA.
  • Syneos Health France, Montrouge, France.
  • Roche Innovation Center Welwyn, Welwyn, UK.

ORCID-Profile: Candice Jamois, David C Turner, Leonid Gibiansky, Feifei Li, Leonardo Roque Pereira, Linda Lundberg, David J Carlile, Nicolas Frey

Förderung

  • F. Hoffmann-La Roche Ltd
  • Roche

Zitieren

APA

Jamois, C., Turner, D. C., Gibiansky, L., Li, F., Menuet, J. F., Pereira, L. R., Lundberg, L., Guerini, E., Carlile, D. J., Relf, J., Wei, M. C., Kwan, A., Frey, N., & Grange, S. (2025). Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3751

Vancouver

Jamois C, Turner DC, Gibiansky L, Li F, Menuet JF, Pereira LR, et al. Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3751

BibTeX
@article{Jamois2025,
  author = {Jamois, Candice and Turner, David C and Gibiansky, Leonid and Li, Feifei and Menuet, Jean-Francois and Pereira, Leonardo Roque and Lundberg, Linda and Guerini, Elena and Carlile, David J and Relf, James and Wei, Michael C and Kwan, Antonia and Frey, Nicolas and Grange, Susan},
  title = {Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3751}
}
Kostenlos starten →